Literature DB >> 33461544

Hypoxia-induced Tie1 drives stemness and cisplatin resistance in non-small cell lung carcinoma cells.

Chaojie Li1, Nannan Yang1, Zhijin Chen1, Ning Xia1, Qungang Shan1, Ziyin Wang1, Jian Lu1, Mingyi Shang2, Zhongmin Wang3,4.   

Abstract

BACKGROUND: Drug resistance and metastasis involving hypoxic tumor environments and persistent stem cell populations are detrimental to the survival of patients with non-small cell lung carcinoma (NSCLC). Tie1 is upregulated in hypoxia and is believed to counteract the effectiveness of platinum agents by promoting the stemness properties in cells. We have investigated the association of Tie1 with HIF-1α and cisplatin resistance in NSCLC cell lines.
METHODS: The expression of Tie1 in a pulmonary microvascular endothelial cell line (HPMEC) and NSCLC cell lines was detected using qRT-PCR and western blotting. The effect of Tie1 on cell stemness and migration was examined by sphere-forming and transwell assays in NSCLC cells with Tie1 silenced. The regulation of Tie1 by HIF-1α was evaluated by a dual-luciferase reporter assay and chromatin immunoprecipitation.
RESULTS: We found that hypoxia could induce stemness and cisplatin resistance in vitro. Tie1 was expressed at low levels in NSCLC cells when compared with human pulmonary microvascular endothelial cells, however, its expression was increased by hypoxia. Additionally, Tie1 knockdown could reduce stemness properties and increase sensitivity to cisplatin in vitro and in a xenograft mouse model. The promoter of Tie1 contains two predicted hypoxia-response elements (HREs). We mutated both HRE sites and conducted chromatin immune-precipitation and promoter luciferase reporter assays and were able to conclude that the induction of Tie1 by hypoxia was HIF-1α-dependent.
CONCLUSIONS: Our findings indicated that Tie1 is upregulated in a hypoxic environment by HIF-1α and contributes to tumorigenesis and cisplatin resistance through the promotion of stemness in NSCLC cells.

Entities:  

Keywords:  Cisplatin resistance; HIF-1α; Hypoxia; Stemness; Tie1

Year:  2021        PMID: 33461544     DOI: 10.1186/s12935-020-01729-3

Source DB:  PubMed          Journal:  Cancer Cell Int        ISSN: 1475-2867            Impact factor:   5.722


  40 in total

Review 1.  Drug resistance in non-small cell lung Cancer (NSCLC): Impact of genetic and non-genetic alterations on therapeutic regimen and responsiveness.

Authors:  Michela Terlizzi; Chiara Colarusso; Aldo Pinto; Rosalinda Sorrentino
Journal:  Pharmacol Ther       Date:  2019-06-19       Impact factor: 12.310

2.  The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification.

Authors:  William D Travis; Elisabeth Brambilla; Andrew G Nicholson; Yasushi Yatabe; John H M Austin; Mary Beth Beasley; Lucian R Chirieac; Sanja Dacic; Edwina Duhig; Douglas B Flieder; Kim Geisinger; Fred R Hirsch; Yuichi Ishikawa; Keith M Kerr; Masayuki Noguchi; Giuseppe Pelosi; Charles A Powell; Ming Sound Tsao; Ignacio Wistuba
Journal:  J Thorac Oncol       Date:  2015-09       Impact factor: 15.609

3.  [Treatment with cephalexin monohydrate of urinary tract infections in children. Preliminary report].

Authors:  J A De La Torre; L Filloy; E Mendez Tena; J Olarte; L Torregrosa
Journal:  Prensa Med Mex       Date:  1970 Sep-Oct

4.  Enhanced intrauterine transmission of herpes simplex virus infection in immunosuppressed hamsters.

Authors:  T Kurata; K Kurata; Y Aoyama
Journal:  Adv Exp Med Biol       Date:  1981       Impact factor: 2.622

Review 5.  Lung Cancer Staging and Prognosis.

Authors:  Gavitt A Woodard; Kirk D Jones; David M Jablons
Journal:  Cancer Treat Res       Date:  2016

6.  The International Epidemiology of Lung Cancer: Latest Trends, Disparities, and Tumor Characteristics.

Authors:  Ting-Yuan David Cheng; Susanna M Cramb; Peter D Baade; Danny R Youlden; Chukwumere Nwogu; Mary E Reid
Journal:  J Thorac Oncol       Date:  2016-06-27       Impact factor: 15.609

Review 7.  Cancer stem cells in drug resistant lung cancer: Targeting cell surface markers and signaling pathways.

Authors:  Gemma Leon; Lauren MacDonagh; Stephen P Finn; Sinead Cuffe; Martin P Barr
Journal:  Pharmacol Ther       Date:  2015-12-17       Impact factor: 12.310

Review 8.  Drug resistance to targeted therapeutic strategies in non-small cell lung cancer.

Authors:  Wen-Juan Liu; Yue Du; Ru Wen; Ming Yang; Jian Xu
Journal:  Pharmacol Ther       Date:  2019-11-09       Impact factor: 12.310

Review 9.  Global Epidemiology of Lung Cancer.

Authors:  Julie A Barta; Charles A Powell; Juan P Wisnivesky
Journal:  Ann Glob Health       Date:  2019-01-22       Impact factor: 2.462

10.  Tyrosine kinase receptor TIE-1 mediates platinum resistance by promoting nucleotide excision repair in ovarian cancer.

Authors:  Masumi Ishibashi; Masafumi Toyoshima; Xuewei Zhang; Junko Hasegawa-Minato; Shogo Shigeta; Toshinori Usui; Christopher J Kemp; Carla Grandori; Kazuyuki Kitatani; Nobuo Yaegashi
Journal:  Sci Rep       Date:  2018-09-04       Impact factor: 4.379

View more
  3 in total

1.  An analysis of the significance of the Tre2/Bub2/CDC 16 (TBC) domain protein family 8 in colorectal cancer.

Authors:  Yuan-Jie Liu; Jie-Pin Li; Hui-Ru Li; Shu-Hong Zeng; Yu-Gen Chen; Mei Han; Qian-Wen Ye; Jin-Yong Zhou; Shen-Lin Liu; Xi Zou
Journal:  Sci Rep       Date:  2022-08-02       Impact factor: 4.996

2.  ITCH facilitates proteasomal degradation of TXNIP in hypoxia- induced lung cancer cells.

Authors:  Qian Sun; Bi-Bo Wang; Wei Wei; Gui-Chun Huang; Lei-Lei Liu; Wei-Wei Chen; Jing Wang; Xiao-Yue Zhao; Lu Lu; Rong Fang; Chun-Yan Zhu; Xiao-Yuan Chu
Journal:  Thorac Cancer       Date:  2022-07-10       Impact factor: 3.223

3.  The road of NSCLC stem cells toward bone metastases.

Authors:  Giulia Bertolini; Ilaria Roato
Journal:  Bone Rep       Date:  2022-09-05
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.